Cocrystal Pharma, Inc.
COCP
$1.31
$0.000.00%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -17.35% | 4.07% | 13.36% | 5.85% | 22.41% |
| Gross Profit | 17.35% | -4.07% | -13.36% | -5.85% | -22.41% |
| SG&A Expenses | -10.83% | -4.46% | -3.17% | 6.73% | 4.26% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -15.51% | 1.60% | 8.50% | 6.11% | 16.66% |
| Operating Income | 15.51% | -1.60% | -8.50% | -6.11% | -16.66% |
| Income Before Tax | 2.67% | -3.78% | 8.32% | 57.93% | 53.69% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 2.67% | -3.78% | 8.32% | 57.93% | 53.69% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 2.67% | -3.78% | 8.32% | 57.93% | 53.69% |
| EBIT | 15.51% | -1.60% | -8.50% | -6.11% | -16.66% |
| EBITDA | 15.35% | -1.91% | -8.73% | -6.24% | -16.81% |
| EPS Basic | 9.35% | 8.83% | 23.57% | 66.26% | 60.20% |
| Normalized Basic EPS | 20.12% | 10.95% | 12.49% | 18.89% | 3.35% |
| EPS Diluted | 9.42% | 8.90% | 23.61% | 66.26% | 60.15% |
| Normalized Diluted EPS | 20.12% | 10.95% | 12.49% | 18.89% | 3.35% |
| Average Basic Shares Outstanding | 5.48% | 11.61% | 18.06% | 24.69% | 18.45% |
| Average Diluted Shares Outstanding | 5.48% | 11.61% | 18.06% | 24.69% | 18.45% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |